Elicio Therapeutics, Inc.
ELTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601485
No open-market purchases or sales by Elicio Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $15.3M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Elicio Therapeutics, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 17
- −1 vs. Q3 2024
- Shares held
- 454.1K
- −37.4K (−7.6%) vs. Q3 2024
- Total value
- $2.25M
- −$224.6K (−9.1%) vs. Q3 2024
- New holders
- 2
- 2 more added
- Sold out
- 3
- 6 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $15.3M |
| Q1 2026 | 47 | $28.2M |
| Q4 2025 | 37 | $16.6M |
| Q3 2025 | 28 | $20.9M |
| Q2 2025 | 21 | $11.2M |
| Q1 2025 | 24 | $9.80M |
| Q4 2024 | 17 | $2.25M |
| Q3 2024 | 18 | $2.48M |
| Q2 2024 | 20 | $2.68M |
| Q1 2024 | 18 | $3.08M |
| Q4 2023 | 18 | $2.78M |
| Q3 2023 | 18 | $2.80M |
| Q2 2023 | 15 | $2.71M |
| Q1 2023 | 28 | $2.56M |
| Q4 2022 | 30 | $3.98M |
| Q3 2022 | 38 | $4.71M |
| Q2 2022 | 43 | $5.90M |
| Q1 2022 | 47 | $13.8M |
| Q4 2021 | 53 | $20.3M |
| Q3 2021 | 47 | $69.3M |
| Q2 2021 | 41 | $66.5M |
| Q1 2021 | 41 | $92.0M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Elicio Therapeutics, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 17 | $87 | 0.00% | −831−98.0% | Reduced |
| JPMorgan Chase & Co | 18 | $88 | 0.00% | 00.0% | Unchanged |
| BNP Paribas Arbitrage, SA | 65 | $332 | 0.00% | +65 | New |
| SBI Securities Co., Ltd. | 83 | $423 | 0.00% | +83 | New |
| Morgan Stanley | 230 | $1.17K | 0.00% | −10−4.2% | Reduced |
| Citigroup Inc | 374 | $1.83K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 611 | $3.12K | 0.00% | −339−35.7% | Reduced |
| Bank of America Corp | 1,197 | $6.11K | 0.00% | −39−3.2% | Reduced |
| Steward Partners Investment Advisory, LLC | 1,554 | $7.92K | 0.00% | 00.0% | Unchanged |
| CIBC Private Wealth Group, LLC | 7,000 | $42.6K | 0.00% | 00.0% | Unchanged |
| Meyer Handelman Co | 13,899 | $70.9K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 19,811 | $101.0K | 0.00% | +118+0.6% | Added |
| State Street Corp | 21,900 | $107.3K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 30,769 | $156.9K | 0.00% | 00.0% | Unchanged |
| CM Management, LLC | 40,000 | $204.0K | 0.18% | −10,000−20.0% | Reduced |
| Geode Capital Management, LLC | 70,721 | $346.6K | 0.00% | −853−1.2% | Reduced |
| Vanguard Group Inc | 245,823 | $1.20M | 0.00% | +561+0.2% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −12,856−100.0% | Sold out |
| Bridgeway Capital Management, LLC | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −800−100.0% | Sold out |